Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reached a key milestone in its ongoing imaging collaboration with Massachusetts General Hospital, as patient enrollment in a pilot study evaluating a novel PET imaging tracer for multiple sclerosis (MS) has reached the halfway mark. The company also reported that preliminary imaging data are encouraging, showing a meaningful signal in MS lesions. This development is significant because the imaging technique could help differentiate between reversible nerve damage and permanent damage, potentially aiding in the development of Lucid-MS, the company's MS drug candidate.
Multiple sclerosis is one of the most common neurological diseases affecting young adults worldwide, with approximately 2.9 million people living with the disease globally, including nearly one million in the United States. Most individuals are diagnosed between the ages of 20 and 40, striking during some of their most productive years. The ability to accurately track disease progression and distinguish between types of nerve damage is crucial for developing effective treatments.
The study uses a novel positron emission tomography (PET) imaging tracer that allows researchers to visualize and differentiate between various types of MS lesions. Early results have shown a promising signal, indicating that the tracer may be effective in identifying active inflammation and neurodegeneration. This could provide a valuable tool for monitoring disease activity and assessing the efficacy of Lucid-MS in clinical trials.
Quantum BioPharma is a biopharmaceutical company focused on neurodegenerative and metabolic disorders. The company's stock is traded on Nasdaq under the symbol QNTM and on the Canadian Securities Exchange under QNTM. For the latest news and updates, visit the company's newsroom at https://nnw.fm/QNTM.
NetworkNewsWire (NNW) is a specialized communications platform with a focus on financial news and content distribution. It is one of over 75 brands within the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions, article syndication to over 5,000 outlets, enhanced press release distribution, social media distribution to millions of followers, and a full array of tailored corporate communications solutions. More information is available at https://www.NetworkNewsWire.com.
